Compare Nautilus Biotechnology, Inc. (NAUT) vs Vertex Pharmaceuticals Incorporated (VRTX) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock

Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 19.0x trailing P/E (17.4x forward), making it the more compelling value choice. Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc. (REGN) is the cheapest at 19.0x versus Vertex Pharmaceuticals Incorporated at 31.2x. On forward P/E, Regeneron Pharmaceuticals, Inc. is actually cheaper at 17.4x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2.75x versus Vertex Pharmaceuticals Incorporated's 2.98x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +125.4%, compared to -81.9% for Nautilus Biotechnology, Inc. (NAUT). A $10,000 investment in VRTX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VRTX returned +425.4% versus NAUT's -74.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Vertex Pharmaceuticals Incorporated (VRTX) is the lower-risk stock at 0.44β versus Nautilus Biotechnology, Inc.'s 1.71β — meaning NAUT is approximately 288% more volatile than VRTX relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 20% for Vertex Pharmaceuticals Incorporated — giving it more financial flexibility in a downturn.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.9% net margin versus 0.0% for Nautilus Biotechnology, Inc. — meaning it keeps 32.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39.1% versus 0.0% for NAUT. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2.75x versus Vertex Pharmaceuticals Incorporated's 2.98x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Regeneron Pharmaceuticals, Inc. (REGN) trades at 17.4x forward P/E versus 24.7x for Vertex Pharmaceuticals Incorporated — 7.3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VRTX: 14.1% to $545.08.

In this comparison, REGN (0.4% yield) pays a dividend. NAUT, VRTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44), +425.4% 10Y return). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1.71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRTX: +425.4%, NAUT: -74.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.